Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
StroVac
- Development stage
- Phase 4
- Lead developer
- Strathmann
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
StroVac is an inactivated bacterial vaccine developed by Strathmann for the prevention and treatment of recurrent urinary tract infections (UTIs). It consists of a suspension of chemically inactivated uropathogenic bacteria, including six different strains of *Escherichia coli*, as well as *Proteus mirabilis*, *Morganella morganii*, *Enterococcus faecalis*, and *Klebsiella pneumoniae*. The vaccine works by inducing a systemic and local mucosal immune response, increasing the production of specific antibodies (primarily secretory IgA) against these common causes of cystitis. It is typically administered via intramuscular injection in a primary series of three doses, followed by a booster (Booster-StroVac) approximately one year later to maintain immunity.
- Brand names
- StroVacBooster-StroVac
Beyond the preview
Go deeper on StroVac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StroVac.